Peak plasma concentration of azithromycin and treatment responses in mycobacterium avium complex lung disease

Byeong Ho Jeong, Kyeongman Jeon, Hye Yun Park, Seong Mi Moon, Su Young Kim, Soo Youn Lee, Sung Jae Shin, Charles L. Daley, Won Jung Koh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Macrolides, such as azithromycin (AZM) and clarithromycin, are the cornerstones of treatment for Mycobacterium avium complex lung disease (MAC-LD). Current guidelines recommend daily therapy with AZM for cavitary MAC-LD and intermittent therapy for noncavitary MAC-LD, but the effectiveness of these regimens has not been thoroughly investigated. This study evaluated associations between microbiological response and estimated peak plasma concentrations (Cmax) of AZM. The AZM Cmax was measured in patients receiving daily therapy (250 mg of AZM daily, n = 77) or intermittent therapy (500 mg of AZM three times weekly, n = 89) for MAC-LD and daily therapy for Mycobacterium abscessus complex LD (MABC-LD) (250 mg of AZM daily, n = 55). The AZM Cmax was lower with the daily regimen for MAC-LD (median, 0.24 μg/ml) than with the intermittent regimen for MAC-LD (median, 0.65 μg/ml; P < 0.001) or daily therapy for MABC-LD (median, 0.53 μg/ml; P < 0.001). After adjusting for confounding factors, AZM Cmax was independently associated with favorable microbiological responses in MAC-LD patients receiving a daily regimen (adjusted odds ratio [aOR], 1.58; 95% confidence interval [CI], 1.01 to 2.48; P = 0.044) but not an intermittent regimen (aOR, 0.85; 95% CI, 0.58 to 1.23, P = 0.379). With the daily AZM-based multidrug regimen for MAC-LD, a low AZM Cmax was common, whereas a higher AZM Cmax was associated with favorable microbiologic responses. The results also suggested that the addition of rifampin may lower AZM Cmax. When a daily AZM-based multidrug regimen is used for treating severe MAC-LD, such as cavitary disease, the currently recommended AZM dose might be suboptimal.

Original languageEnglish
Pages (from-to)6076-6083
Number of pages8
JournalAntimicrobial agents and chemotherapy
Volume60
Issue number10
DOIs
Publication statusPublished - 2016 Oct

Fingerprint

Mycobacterium avium Complex
Azithromycin
Lung Diseases
Therapeutics
Mycobacterium
Odds Ratio
Confidence Intervals
Clarithromycin
Macrolides
Rifampin

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Jeong, Byeong Ho ; Jeon, Kyeongman ; Park, Hye Yun ; Moon, Seong Mi ; Kim, Su Young ; Lee, Soo Youn ; Shin, Sung Jae ; Daley, Charles L. ; Koh, Won Jung. / Peak plasma concentration of azithromycin and treatment responses in mycobacterium avium complex lung disease. In: Antimicrobial agents and chemotherapy. 2016 ; Vol. 60, No. 10. pp. 6076-6083.
@article{f37ac82030de4023a621158e560839bb,
title = "Peak plasma concentration of azithromycin and treatment responses in mycobacterium avium complex lung disease",
abstract = "Macrolides, such as azithromycin (AZM) and clarithromycin, are the cornerstones of treatment for Mycobacterium avium complex lung disease (MAC-LD). Current guidelines recommend daily therapy with AZM for cavitary MAC-LD and intermittent therapy for noncavitary MAC-LD, but the effectiveness of these regimens has not been thoroughly investigated. This study evaluated associations between microbiological response and estimated peak plasma concentrations (Cmax) of AZM. The AZM Cmax was measured in patients receiving daily therapy (250 mg of AZM daily, n = 77) or intermittent therapy (500 mg of AZM three times weekly, n = 89) for MAC-LD and daily therapy for Mycobacterium abscessus complex LD (MABC-LD) (250 mg of AZM daily, n = 55). The AZM Cmax was lower with the daily regimen for MAC-LD (median, 0.24 μg/ml) than with the intermittent regimen for MAC-LD (median, 0.65 μg/ml; P < 0.001) or daily therapy for MABC-LD (median, 0.53 μg/ml; P < 0.001). After adjusting for confounding factors, AZM Cmax was independently associated with favorable microbiological responses in MAC-LD patients receiving a daily regimen (adjusted odds ratio [aOR], 1.58; 95{\%} confidence interval [CI], 1.01 to 2.48; P = 0.044) but not an intermittent regimen (aOR, 0.85; 95{\%} CI, 0.58 to 1.23, P = 0.379). With the daily AZM-based multidrug regimen for MAC-LD, a low AZM Cmax was common, whereas a higher AZM Cmax was associated with favorable microbiologic responses. The results also suggested that the addition of rifampin may lower AZM Cmax. When a daily AZM-based multidrug regimen is used for treating severe MAC-LD, such as cavitary disease, the currently recommended AZM dose might be suboptimal.",
author = "Jeong, {Byeong Ho} and Kyeongman Jeon and Park, {Hye Yun} and Moon, {Seong Mi} and Kim, {Su Young} and Lee, {Soo Youn} and Shin, {Sung Jae} and Daley, {Charles L.} and Koh, {Won Jung}",
year = "2016",
month = "10",
doi = "10.1128/AAC.00770-16",
language = "English",
volume = "60",
pages = "6076--6083",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

Peak plasma concentration of azithromycin and treatment responses in mycobacterium avium complex lung disease. / Jeong, Byeong Ho; Jeon, Kyeongman; Park, Hye Yun; Moon, Seong Mi; Kim, Su Young; Lee, Soo Youn; Shin, Sung Jae; Daley, Charles L.; Koh, Won Jung.

In: Antimicrobial agents and chemotherapy, Vol. 60, No. 10, 10.2016, p. 6076-6083.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peak plasma concentration of azithromycin and treatment responses in mycobacterium avium complex lung disease

AU - Jeong, Byeong Ho

AU - Jeon, Kyeongman

AU - Park, Hye Yun

AU - Moon, Seong Mi

AU - Kim, Su Young

AU - Lee, Soo Youn

AU - Shin, Sung Jae

AU - Daley, Charles L.

AU - Koh, Won Jung

PY - 2016/10

Y1 - 2016/10

N2 - Macrolides, such as azithromycin (AZM) and clarithromycin, are the cornerstones of treatment for Mycobacterium avium complex lung disease (MAC-LD). Current guidelines recommend daily therapy with AZM for cavitary MAC-LD and intermittent therapy for noncavitary MAC-LD, but the effectiveness of these regimens has not been thoroughly investigated. This study evaluated associations between microbiological response and estimated peak plasma concentrations (Cmax) of AZM. The AZM Cmax was measured in patients receiving daily therapy (250 mg of AZM daily, n = 77) or intermittent therapy (500 mg of AZM three times weekly, n = 89) for MAC-LD and daily therapy for Mycobacterium abscessus complex LD (MABC-LD) (250 mg of AZM daily, n = 55). The AZM Cmax was lower with the daily regimen for MAC-LD (median, 0.24 μg/ml) than with the intermittent regimen for MAC-LD (median, 0.65 μg/ml; P < 0.001) or daily therapy for MABC-LD (median, 0.53 μg/ml; P < 0.001). After adjusting for confounding factors, AZM Cmax was independently associated with favorable microbiological responses in MAC-LD patients receiving a daily regimen (adjusted odds ratio [aOR], 1.58; 95% confidence interval [CI], 1.01 to 2.48; P = 0.044) but not an intermittent regimen (aOR, 0.85; 95% CI, 0.58 to 1.23, P = 0.379). With the daily AZM-based multidrug regimen for MAC-LD, a low AZM Cmax was common, whereas a higher AZM Cmax was associated with favorable microbiologic responses. The results also suggested that the addition of rifampin may lower AZM Cmax. When a daily AZM-based multidrug regimen is used for treating severe MAC-LD, such as cavitary disease, the currently recommended AZM dose might be suboptimal.

AB - Macrolides, such as azithromycin (AZM) and clarithromycin, are the cornerstones of treatment for Mycobacterium avium complex lung disease (MAC-LD). Current guidelines recommend daily therapy with AZM for cavitary MAC-LD and intermittent therapy for noncavitary MAC-LD, but the effectiveness of these regimens has not been thoroughly investigated. This study evaluated associations between microbiological response and estimated peak plasma concentrations (Cmax) of AZM. The AZM Cmax was measured in patients receiving daily therapy (250 mg of AZM daily, n = 77) or intermittent therapy (500 mg of AZM three times weekly, n = 89) for MAC-LD and daily therapy for Mycobacterium abscessus complex LD (MABC-LD) (250 mg of AZM daily, n = 55). The AZM Cmax was lower with the daily regimen for MAC-LD (median, 0.24 μg/ml) than with the intermittent regimen for MAC-LD (median, 0.65 μg/ml; P < 0.001) or daily therapy for MABC-LD (median, 0.53 μg/ml; P < 0.001). After adjusting for confounding factors, AZM Cmax was independently associated with favorable microbiological responses in MAC-LD patients receiving a daily regimen (adjusted odds ratio [aOR], 1.58; 95% confidence interval [CI], 1.01 to 2.48; P = 0.044) but not an intermittent regimen (aOR, 0.85; 95% CI, 0.58 to 1.23, P = 0.379). With the daily AZM-based multidrug regimen for MAC-LD, a low AZM Cmax was common, whereas a higher AZM Cmax was associated with favorable microbiologic responses. The results also suggested that the addition of rifampin may lower AZM Cmax. When a daily AZM-based multidrug regimen is used for treating severe MAC-LD, such as cavitary disease, the currently recommended AZM dose might be suboptimal.

UR - http://www.scopus.com/inward/record.url?scp=84992736382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992736382&partnerID=8YFLogxK

U2 - 10.1128/AAC.00770-16

DO - 10.1128/AAC.00770-16

M3 - Article

C2 - 27480854

AN - SCOPUS:84992736382

VL - 60

SP - 6076

EP - 6083

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -